08:00 , Nov 10, 2014 |  BC Week In Review  |  Clinical News

ARA 290 regulatory update

FDA granted Fast Track designation to Araim's ARA 290 to treat sarcoidosis-associated small fiber neuropathy. The short tissue protective peptide is in Phase IIb testing for the indication, with Phase III testing slated for 4Q15....
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

ARA 290 regulatory update

The European Commission granted Orphan Drug designation to Araim's ARA 290 to treat sarcoidosis. The short tissue protective peptide is in Phase IIb testing for small fiber neuropathy in sarcoidosis patients and Phase IIa testing...
08:00 , Feb 21, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Dermatology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Burns Erythropoietin (EPO); colony stimulating factor 2 receptor-b low-affinity (CSF2RB; CD131) Mouse...